dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Peralta-Garcia, Alejandro |
dc.contributor.author | Torrens-Fontanals, Mariona |
dc.contributor.author | Stepniewski, Tomasz Maciej |
dc.contributor.author | Grau Exposito, Judit |
dc.contributor.author | Perea Pérez, David |
dc.contributor.author | Ayinampudi, Vikram |
dc.contributor.author | Buzón Gómez, María José |
dc.contributor.author | Genesca Ferrer, Meritxell |
dc.date.accessioned | 2022-06-15T11:45:19Z |
dc.date.available | 2022-06-15T11:45:19Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, et al. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci. 2021 Dec;22(24):13592. |
dc.identifier.issn | 1422-0067 |
dc.identifier.uri | https://hdl.handle.net/11351/7684 |
dc.description | COVID-19; Reutilización de medicamentos; Ensayos de entrada de células virales |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | International Journal of Molecular Sciences;22(24) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments antivírics |
dc.subject | COVID-19 (Malaltia) |
dc.subject | Medicaments - Ús |
dc.subject.mesh | Antiviral Agents |
dc.subject.mesh | /pharmacology |
dc.subject.mesh | Drug Repositioning |
dc.subject.mesh | Coronavirus Infections |
dc.title | Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/ijms222413592 |
dc.subject.decs | antivíricos |
dc.subject.decs | /farmacología |
dc.subject.decs | nuevas indicaciones de medicamentos |
dc.subject.decs | infecciones por Coronavirus |
dc.relation.publishversion | https://doi.org/10.3390/ijms222413592 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Peralta-Garcia A, Torrens-Fontanals M] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. [Stepniewski TM] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland. [Grau-Expósito J, Perea D, Buzón MJ, Genescà M] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ayinampudi V] InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland |
dc.identifier.pmid | 34948390 |
dc.identifier.wos | 000737887800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |